
Asthma-COPD Overlap Syndrome: Sharpen Suspicion in Primary Care
ACOS is often first suspected in the primary care setting. Experts at CHEST 2015 reviewed the syndrome, who is at risk, and treatment challenges.
Obstructive lung disease is divided in asthma (reversible) and chronic obstructive pulmonary disease (COPD [nonreversible]), but in clinical practice this distinction is often difficult to make-especially in older patients. In about 20% of patients, asthma and COPD may coexist. In the session titled “Asthma-COPD overlap syndrome: A new disease or old news?” at the 2015 American College of Chest Physicians meeting in Montreal, a group of experts clarified the clinical manifestations, ramifications, and treatment of this overlap syndrome.
Asthma-COPD overlap syndrome (ACOS), as defined by the Global Initiative for Chronic Obstructive Lung Disease (
Knowledge of ACOS at the primary care level is essential; the GOLD guidelines note that the primary care physician may be the first to suspect or identify ACOS. A
The distinction between asthma, COPD, and ACOS is often a difficult one to make. Bronchodilator (BD) responsiveness, which is classically reported in early asthma, is also seen in about 60% of COPD patients. Irreversible airway obstruction, which is classically reported in COPD patients, is often seen in patients with long-standing asthma. Sputum eosinophil count and exhaled nitric oxide are also often elevated in COPD and do not help in distinguishing among the three entities. Patients with ACOS are usually older with a significant smoking history. Spirometry may show incomplete reversibility of obstruction with positive BD response. ACOS patients have been found to have less emphysema, greater airway wall thickness, and more gas trapping than COPD patients. Epidemiologic data, biomarkers, genetic and genomic studies suggest that ACOS shares inflammatory markers with asthma.
Treatment guidelines provide scant advice on how these patients should be managed. ACOS patients have been specifically excluded from clinical trials of asthma and COPD treatments. No double blind, prospective trials have been done with ACOS patients. Treatment guidelines for COPD and asthma as recommended by GOLD and GINA respectively can be followed. Dr. Stephen Bernard from University of Nebraska concluded, “If you got it, treat it and if you got both, treat both.”
References:
Panel presentation. The asthma-COPD overlap syndrome: A new disease or old news? Presentation at 2015 American College of Chest Physicians Conference – CHEST 2015; October 25, 2015; Montreal, Canada.
Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373:1241-1249. doi: 10.1056/NEJMra1411863. Review. PubMed PMID: 26398072.
Kiljander T, HelinT, Venho K, et al. Prevalence of asthma–COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. npj Primary Care Resp Med. (2015) 25, 15047; doi:10.1038/npjpcrm.2015.47; published online 16 July 2015 http://www.nature.com/articles/npjpcrm201547
GINA-GOLD consensus document:
GINA reports:
GOLD reports:
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.































































































































































































































































































